生物制药企业Skye Bioscience Inc. (NASDAQ: SKYE) 近日迎来重大研发进展——其针对尼玛西单抗（nimacimab）开展的高剂量扩展研究已完成首例患者给药。该研究旨在通过评估药物暴露-反应关系，为后续GLP-1联合疗法的二期B阶段临床实验确定最佳剂量方案提供关键数据支持。
此次剂量扩展研究的启动，标志着Skye Bioscience在代谢性疾病治疗领域迈出实质性步伐。通过精准分析不同剂量水平下尼玛西单抗在人体内的代谢动力学与药效学关联，研究团队期望为二期B阶段剂量选择奠定科学基础，进而加速GLP-1受体激动剂联合疗法的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.